How does OGEN's PB Ratio compare to its peers?

OGEN is expensive based on its Price-To-Book Ratio (2.3x) compared to the peer average (0.6x).

How does OGEN's PB Ratio compare vs other companies in the US Biotechs Industry?

OGEN is expensive based on its Price-To-Book Ratio (2.3x) compared to the US Biotechs industry average (1.8x).

What is OGEN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate OGEN's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of OGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate OGEN's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Oragenics (NYSEAM:OGEN) - Stock Price, News & Analysis

OGEN Stock Overview

A development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. More details

OGEN fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($3M)

Oragenics, Inc. Competitors

Gritstone bio

OTCPK:GRTS.Q

US$3.2m

Oncternal Therapeutics

NasdaqCM:ONCT

US$3.4m

Bionomics

NasdaqGM:BNOX

US$4.8m

Organovo Holdings

NasdaqCM:ONVO

US$5.4m

Price History & Performance

Summary of all time highs, changes and price drops for Oragenics
Historical stock prices
Current Share Price	US$0.27
52 Week High	US$7.74
52 Week Low	US$0.25
Beta	0.48
11 Month Change	-16.05%
3 Month Change	-73.14%
1 Year Change	-92.39%
33 Year Change	-99.17%
5 Year Change	-99.26%
Change since IPO	-100.00%

Recent updates

Shareholder Returns

	OGEN	US Biotechs	US Market
7D	-14.6%	2.4%	2.2%
1Y	-92.4%	16.2%	31.7%

Return vs Industry: OGEN underperformed the US Biotechs industry which returned 15.2% over the past year.

Return vs Market: OGEN underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is OGEN's price volatile compared to industry and market?
OGEN volatility
OGEN Average Weekly Movement	19.9%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: OGEN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: OGEN's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1996	5	Mike Redmond	www.oragenics.com

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics.

Oragenics, Inc. Fundamentals Summary

How do Oragenics's earnings and revenue compare to its market cap?
OGEN fundamental statistics
Market cap	US$3.30m
Earnings (TTM)	-US$19.97m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is OGEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OGEN income statement (TTM)
Revenue	US$0
Cost of Revenue	US$15.49m
Gross Profit	-US$15.49m
Other Expenses	US$4.48m
Earnings	-US$19.97m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.63
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	16.9%

How did OGEN perform over the long term?

See historical performance and comparison

OGEN Stock Overview

Risk Analysis

Oragenics, Inc. Competitors

OTCPK:GRTS.Q

US$3.2m

NasdaqCM:ONCT

US$3.4m

NasdaqGM:BNOX

US$4.8m

NasdaqCM:ONVO

US$5.4m

Price History & Performance

Recent News & Updates

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Oragenics, Inc. Plans to Initiate Phase II Clinical Trials

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Recent updates

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Oragenics, Inc. Plans to Initiate Phase II Clinical Trials

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics, Inc. has filed a Follow-on Equity Offering in the amount of $4.453593 million.

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

New major risk - Financial position

First half 2024 earnings released: US$1.21 loss per share (vs US$2.92 loss in 1H 2023)

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients

Oragenics, Inc. has completed a Follow-on Equity Offering.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics Announces NYSE American Acceptance of Plan of Compliance

Oragenics, Inc. Appoints William “Frank” Peacock MD as Chief Clinical Officer

Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial

First quarter 2024 earnings released: US$0.70 loss per share (vs US$1.41 loss in 1Q 2023)

Full year 2023 earnings released: US$9.18 loss per share (vs US$7.11 loss in FY 2022)

Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $2.1 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. Announces Leadership Transition

Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion

New major risk - Share price stability

Oragenics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Oragenics, Inc. has filed a Follow-on Equity Offering.

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Third quarter 2023 earnings released: US$0.85 loss per share (vs US$1.99 loss in 3Q 2022)

Oragenics, Inc., Annual General Meeting, Dec 14, 2023

Oragenics Announces Directorate Appointments

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Second quarter 2023 earnings released: US$1.51 loss per share (vs US$1.85 loss in 2Q 2022)

Oragenics, Inc. announced that it has received $0.85 million in funding

Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate

Insufficient new directors

Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. Reports Favorable Toxicology Results for Its Covid-19 Intranasal Vaccine Candidate

Oragenics, Inc. Receives NYSE American Notice Regarding Compliance with Section 1003(f)(v)

Oragenics, Inc. Announces Board Changes

Oragenics, Inc. Appoints Kimberly Murphy as Secretary and Treasurer

Oragenics, Inc. Announces Resignation of Michael Sullivan as Chief Financial Officer, Effective from December 14, 2022

Price target increased to US$2.25

Oragenics, Inc., Annual General Meeting, Dec 16, 2022

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

Price target increased to US$2.25

Oragenics, Inc. Appoints Kimberly M. Murphy as Chief Executive Officer

Oragenics Announces Publication of Positive Data for Its NT-Cov2-1 Intranasal Covid-19 Vaccine Candidate in Scientific Reports

Price target decreased to US$2.25

Executive Chairman recently bought US$66k worth of stock

Price target decreased to US$2.25

Oragenics Announces Positive Data on Their Intranasal SARS-CoV-2 Vaccine Candidate in a Posted Preprint Manuscript

Oragenics, Inc. Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations SARS-CoV-2 Vaccine Candidate

Price target increased to US$2.25

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Shareholder Returns

Price Volatility

About the Company

Oragenics, Inc. Fundamentals Summary